Diagnostic Medical Systems SA

Diagnostic Medical Systems SA has a fully diluted share count of 26.69 million shares, with no difference between basic and diluted shares outstanding, indicating no dilution risk from stock options or convertible instruments. The company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents, which limits the ability to evaluate its short-term financial stability.

The company's profitability and return metrics are not available in the valuation snapshot, making it difficult to compare its performance against industry_config preferred metrics or cohort medians. Without data on return on invested capital (ROIC), gross margins, or operating margins, it is not possible to assess whether the company is generating returns in line with or above industry norms.

Diagnostic Medical Systems derives its revenue primarily from the sale of radiopharmaceuticals, with a focus on Ga-68 DOTATATE and Lu-177 DOTATATE. The company's geographic exposure is not disclosed in the available data, but its operations are likely concentrated in Europe, given its listing on the Paris stock exchange and the nature of its product offerings.

The company's growth trajectory is not quantified in the outlook data, as no numeric deltas or forward-looking revenue guidance is provided. However, the development and commercialization of radiopharmaceuticals for neuroendocrine tumors suggest a niche but high-growth potential market, particularly as demand for precision oncology treatments increases.

The risk assessment indicates a low dilution potential, with no evidence of recent equity issuance or dilutive instruments. However, the absence of liquidity data and the lack of balance-sheet inputs raise concerns about the company's ability to meet short-term obligations. No specific risk factors are disclosed in the source documents, which limits the ability to evaluate operational or regulatory risks.

Recent events, including analyst estimates and price targets, suggest a generally positive sentiment among analysts. The mean price target of 2.10 EUR and a mean recommendation of 1.50 (on a 1-5 scale) indicate a "strong buy" to "buy" consensus, with no "hold" or negative recommendations reported.

Revenue €50.0M, +8,5% YoY; Operating income +440,5% YoY.

• ▍Revenue €50.0M, +8,5% YoY
• ▍Operating income +440,5% YoY
• ▍Net income +94,2% YoY
• ▍Free cash flow +1 091,0% YoY
• ▍Net margin -0.3%

Revenue €46.1M, +9,3% YoY; Operating income +84,7% YoY.

• ▍Revenue €46.1M, +9,3% YoY
• ▍Operating income +84,7% YoY
• ▍Net income +41,8% YoY
• ▍Free cash flow +95,6% YoY
• ▍Net margin -6.3%

Revenue €42.2M, +19,5% YoY; Operating income +61,5% YoY.

• ▍Revenue €42.2M, +19,5% YoY
• ▍Operating income +61,5% YoY
• ▍Net income +27,5% YoY
• ▍Free cash flow −72,8% YoY
• ▍Net margin -11.7%

Revenue €35.3M, −4,6% YoY; Operating income −63,4% YoY.

• ▍Revenue €35.3M, −4,6% YoY
• ▍Operating income −63,4% YoY
• ▍Net income −76,0% YoY
• ▍Free cash flow −1 727,5% YoY
• ▍Net margin -19.3%